Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for metabolic risk in adults with psychosis at risk of type 2 diabetes
ACTRN12621001434886Phase 4Recruiting
- Sponsor
- South Eastern Sydney Local Health District
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in cardiometabolic risk (CMR), prediabetes and obesity (2 arms), sponsored by South Eastern Sydney Local Health District. Primary endpoints: Change in body weight, Body fat composition at week 24 and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
cardiometabolic risk (CMR)prediabetesobesity
Beyond the preview
Go deeper on ACTRN12621001434886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001434886.